Mizuho Begins Coverage on MiniMed Group (NASDAQ:MMED)

Equities research analysts at Mizuho initiated coverage on shares of MiniMed Group (NASDAQ:MMED) in a report issued on Tuesday, MarketBeat reports. The brokerage set an “outperform” rating and a $21.00 price target on the stock. Mizuho’s price target points to a potential upside of 45.03% from the company’s current price.

Several other equities research analysts also recently weighed in on the company. Bank of America assumed coverage on MiniMed Group in a report on Tuesday. They set a “buy” rating and a $27.00 price target on the stock. Piper Sandler began coverage on MiniMed Group in a research note on Tuesday. They issued a “neutral” rating and a $16.00 price objective for the company. Wall Street Zen upgraded shares of MiniMed Group to a “hold” rating in a research note on Saturday, March 14th. Finally, BTIG Research initiated coverage on shares of MiniMed Group in a report on Tuesday. They issued a “buy” rating and a $25.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Price Performance

MiniMed Group stock opened at $14.48 on Tuesday. MiniMed Group has a twelve month low of $14.10 and a twelve month high of $20.48.

Key Stories Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Bank of America initiated coverage with a Buy rating and a $27 price target, highlighting pipeline-driven growth after the Medtronic separation. Article Title
• Positive Sentiment: Barclays started covering MMED with an Overweight rating and a $26 target, signaling strong upside expectations. Article Title
• Positive Sentiment: Wells Fargo initiated coverage with an Overweight rating and a $26 price target, aligning with other firms on material upside potential. Article Title
• Positive Sentiment: Goldman Sachs initiated a Buy rating with a $24 target, another high-profile bank backing the story. Article Title
• Positive Sentiment: BTIG, Citigroup and Mizuho all opened coverage with Buy/Outperform calls and targets in the low-to-mid $20s, adding to the consensus of meaningful upside from current levels. Article Title
• Positive Sentiment: Evercore, Deutsche Bank and Morgan Stanley also initiated coverage with Outperform/Buy or Overweight views and targets between $19–$21, broadening institutional coverage. Article Title
• Neutral Sentiment: Piper Sandler set a Neutral/16 price target and, separately noted by TipRanks, issued a Hold—this is a more cautious view relative to the slate of Buy calls. Article Title
• Negative Sentiment: Despite the bullish analyst initiation wave, the stock is trading down today — suggesting short-term selling, profit-taking, or market-wide weakness is offsetting the new coverage (no single negative company-specific event reported).

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.